ETV1 and ERG fusions are present throughout the progression of prostate cancer [38, 39, 40, 41], while MET, whose expression is repressed by the androgen receptor, appears mainly in advanced PCa and bone metastasis [42]. Here, ERG is linked to prostate carcinoma.